Axsome Therapeutics (AXSM) Research & Development (2015 - 2026)

Axsome Therapeutics has reported Research & Development for 12 years, with the latest figure at $52.7 million in Q1 2026.

• Quarterly Research & Development rose 17.62% year-over-year to $52.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $145.0 million (down 25.66% YoY) and the FY2025 annual result came in at $183.3 million, down 2.03% from the prior year.
• Research & Development rose to $52.7 million in Q1 2026 per AXSM's latest filing, from $2.6 million in the prior quarter.
• Over five years, Research & Development peaked at $55.0 million in Q4 2024 and troughed at $2.6 million in Q4 2025.
• A 5-year average of $31.3 million and a median of $30.8 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development soared 142.23% in 2024, then plunged 95.27% in 2025.
• Over 5 years, Research & Development stood at $14.7 million in 2022, then soared by 109.64% to $30.8 million in 2023, then soared by 78.57% to $55.0 million in 2024, then slumped by 95.27% to $2.6 million in 2025, then jumped by 1926.04% to $52.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $52.7 million, $2.6 million, and $40.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.